Vanda's Imsidolimab Gains Orphan Drug Status in Europe for Rare…

Event summary

Vanda Pharmaceuticals' imsidolimab received Orphan Designation from the European Commission for treating Generalized Pustular Psoriasis (GPP).
This is the first orphan drug designation for GPP in the EU, following similar designations in the US and Japan.
Imsidolimab is a fully humanized IgG4 monoclonal antibody targeting IL-36 receptor signaling.
The FDA is reviewing imsidolimab's Biologics License Application (BLA) with a target action date of December 12, 2026.

The big picture

Vanda's Orphan Designation for imsidolimab in the EU marks a significant step in addressing Generalized Pustular Psoriasis, a severe and rare inflammatory skin disease. This designation aligns with broader industry trends toward developing targeted therapies for orphan indications, which often come with regulatory incentives and market exclusivity. The strategic context is further strengthened by the drug's simultaneous recognition in the US and Japan, positioning Vanda to potentially capture a global market for this unmet medical need.

What we're watching

Regulatory Momentum: Whether the European Commission's designation will accelerate imsidolimab's approval process in the EU, following similar recognitions in the US and Japan.
Market Exclusivity: The extent to which the orphan drug designation will provide Vanda with market exclusivity and reduced regulatory fees in the EU.
Clinical Success: The pace at which Vanda can demonstrate the efficacy and safety of imsidolimab in treating GPP, particularly as the FDA review progresses.